cadonilimab   Click here for help

GtoPdb Ligand ID: 12966

Synonyms: AK-104 | AK104
Approved drug Immunopharmacology Ligand
cadonilimab is an approved drug (China NMPA (2022))
Compound class: Antibody
Comment: Cadonilimab (AK104) is a humanized, bispecific monoclonal antibody that simultaneously targets the immune checkpoint proteins PD-1 and CTLA-4. It was designed as a cancer immunotherapy (immuno-oncology) agent.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Cadonilimab (AK104) was progressed to clinical evaluation as a therapy for advanced and hard to treat solid tumours, either as a monotherapy or in combination with other cancer drugs or investigational agents. A study in peripheral T-cell lymphoma was terminated due to difficuty in enrolling participants.
In June 2022 cadonilimab was approved by the China National Medical Products Administration as a treatment for recurrent or metastatic cervical cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03261011 Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors Phase 1 Interventional Akeso 1
NCT05594914 AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma Phase 2 Interventional The First Affiliated Hospital of University of South China
NCT04220307 A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Phase 2 Interventional Akeso
NCT04728321 A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2 Interventional Akeso
NCT04172454 Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors Phase 1/Phase 2 Interventional Akeso 3